Ultra纳斯达克生物科(BIB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BIB Ultra纳斯达克生物科

未开盘 10-01 16:00:00 EDT

110.47

-4.98

-4.32%

盘后110.88

+0.41+0.37%

19:30 EDT

最高113.93	最低110.47	成交量5,078
今开113.93	昨收115.45	日振幅3.00%
总市值9,279万	流通市值9,279万	总股本84.00万
成交额57.40万	换手率0.60%	流通股本84.00万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BIB","market":"US","secType":"STK","nameCN":"Ultra纳斯达克生物科","latestPrice":110.4686,"timestamp":1790884800000,"preClose":115.4524,"halted":0,"volume":5078,"hourTrading":{"tag":"盘后","latestPrice":110.88,"preClose":110.4686,"latestTime":"19:30 EDT","volume":135,"amount":14974.343,"timestamp":1790897406056,"change":0.4114,"changeRate":0.003724,"amplitude":0},"delay":0,"changeRate":-0.043167573822631686,"floatShares":840000,"shares":840000,"eps":0,"marketStatus":"未开盘","change":-4.9838,"latestTime":"10-01 16:00:00 EDT","open":113.93,"high":113.93,"low":110.4686,"amount":574022.0456600001,"amplitude":0.029981,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1790928000000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":115.4524,"sharesOutstanding":1040000,"nav":115.2363,"aum":96798492,"dividendRate":0.001989,"bidAskSpread":0.002808,"preHourTrading":{"tag":"盘前","latestPrice":114.27,"preClose":115.4524,"latestTime":"04:44 EDT","volume":8,"amount":914.16,"timestamp":1790844267605,"change":-1.1824,"changeRate":-0.010241,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":110.88,"preClose":110.4686,"latestTime":"19:30 EDT","volume":135,"amount":14974.343,"timestamp":1790897406056,"change":0.4114,"changeRate":0.003724,"amplitude":0},"volumeRatio":0.813965,"impliedVol":0.4915,"impliedVolPercentile":0.7649},"requestUrl":"/m/hq/s/BIB","defaultTab":"news","newsList":[{"id":"2669453169","title":"安进一种自身免疫药物在后期临床试验达到主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2669453169","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669453169?lang=zh_cn&edition=full","pubTime":"2026-09-24 10:32","pubTimestamp":1790217159,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2242646821.SGD","IE0009355771.USD","IE00B2B36J28.USD","LU0058720904.USD","MDTX","IE00BFTCPJ56.SGD","BBH","LU0109394709.USD","LU0868494617.USD","BK4566","IBBJ","LU0122379950.USD","LU1057294990.SGD","LU0889565916.HKD","BK4599","BK4534","LU2112291526.USD","BK4588","IE0002141913.USD","IE00BJJMRZ35.SGD","PJP","PBE","IBB","SG9999001440.SGD","BK4585","LU1983299246.USD","BK4139","BK4533","TBXU","IBBQ","LU0289739699.SGD","PSYK","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","AMGN","BMED","LU1571399168.USD","BK4581","LU2468319806.SGD","LU0320765992.SGD","LU1023059063.AUD","BIB","LU2089984988.USD","LU2242652126.USD","LU1061106388.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121969920","title":"安进宣布Dazodalibep在干燥综合征III期试验中达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1121969920","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121969920?lang=zh_cn&edition=full","pubTime":"2026-09-22 21:50","pubTimestamp":1790085037,"startTime":"0","endTime":"0","summary":"路透社9月22日消息——安进公司（Amgen Inc）于近日披露其关键临床进展：\n安进旗下药物Dazodalibep在针对中重度症状性干燥综合征的III期OASIZ 303研究中，成功达到主要终点，该项试验预计将于2026年第四季度完成。\n安进表示，Dazodalibep在III期干燥综合征试验中取得主要终点的积极结果，该药物在系统性疾活动度方面展现出具有统计学显著性及临床意义的改善。\n值得注意的是，这一进展为干燥综合征患者群体带来了新的治疗希望。安进公司股票代码为AMGN.O。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","SG9999001440.SGD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0320765992.SGD","LU2089984988.USD","LU2242652126.USD","BK4566","LU0868494617.USD","BBH","LU1571399168.USD","BK4599","IE00BFTCPJ56.SGD","BIB","LU1983299246.USD","LU2112291526.USD","IBB","BK4585","BK4534","LU0058720904.USD","IE0002141913.USD","BK4533","BK4588","BK4581","LU0289739699.SGD","LU1061106388.HKD","IE00B4R5TH58.HKD","AMGN","IE0009355771.USD","LU0109394709.USD","LU0122379950.USD","LU2468319806.SGD","BK4139","LU1057294990.SGD","PJP","LU2242646821.SGD","TBXU","PBE","IBBQ","IE00BJT1NW94.SGD","LU1023059063.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669114208","title":"安进股价盘前大涨逾4%，受第三期临床试验结果提振。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669114208","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669114208?lang=zh_cn&edition=full","pubTime":"2026-09-22 21:07","pubTimestamp":1790082475,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0109394709.USD","MRNY","BME","PBPH","LFSC","BBH","IBBQ","HELX","IYH","LU0122379950.USD","LU2242646821.SGD","IBRN","PBE","PSCH","SBIO","BBP","XPH","SYNB","IBB","RXL","TBXU","LU2473716301.USD","LU0320765992.SGD","MEDI","BK4585","FTXH","LU0058720904.USD","GNOM","FBT","IE00B5TLWC47.USD","XBIX","PJP","BK4599","BIB","LU2272731782.SGD","WDNA","MRNX","RSPH","IEIH","LU2272731865.HKD","PPH","AZNH","IE00B4R5TH58.HKD","AMGN","IEHS","LU1992135472.HKD","IDNA","TMED","CANC","BIOY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198157419","title":"福泰制药宣布Inaxaplin在特定AMKD患者群体中取得积极结果，第13周UACR显著降低42.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1198157419","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198157419?lang=zh_cn&edition=full","pubTime":"2026-09-22 21:06","pubTimestamp":1790082369,"startTime":"0","endTime":"0","summary":"路透社9月22日消息——福泰制药 今日发布重大公告，披露其在APOL1介导肾病额外患者群体中开展的2b期AMPLIFIED研究取得积极成果。详细数据显示，对于伴有中度蛋白尿的AMKD患者，Inaxaplin在治疗第13周时使尿白蛋白肌酐比较基线下降了42.7%。两项研究队列均显示，Inaxaplin总体安全性和耐受性良好，未出现意外安全信号。值得注意的是，这是福泰制药在这两个特定亚群中首次公布Inaxaplin的临床数据，进一步拓展了该药物在AMKD治疗领域的潜在应用范围。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237438978.USD","LU2468319806.SGD","LU1069344957.HKD","GNMX","VRTX","IE00B19Z9Z06.USD","LU0432979614.USD","IE00B894F039.SGD","LU1778281490.HKD","SG9999013999.USD","IE00B19Z9P08.USD","IE0002270589.USD","IE00B19Z3B42.SGD","LU2456880835.USD","IBBQ","IE0009355771.USD","LU1430594728.SGD","LU1585245621.USD","LU0061475181.USD","PBE","IE00BJT1NW94.SGD","LU2462157665.USD","IBB","LU0823416689.USD","IE00BJJMRZ35.SGD","LU0079474960.USD","LU2236285917.USD","BK4533","SG9999001176.SGD","LU0109394709.USD","BK4139","BK4585","BK4532","LU0234570918.USD","LU2089984988.USD","BK4567","LU0320765992.SGD","SG9999001176.USD","LU0058720904.USD","LU2417539215.USD","IDNA","LU1674673428.USD","LU0889565916.HKD","IE00B19Z3581.USD","IE00B2B36J28.USD","LU2362541513.USD","LU1674673691.USD","LU2324357040.USD","LU1093756325.SGD","LU2362541273.HKD","IE00BFTCPJ56.SGD","LU1035775433.USD","LU0417517546.SGD","IE00B4R5TH58.HKD","IE00BZ9MQY76.HKD","LU2362540622.SGD","BK4588","SGXZ57979304.SGD","LU0256863811.USD","LU0289739699.SGD","BIB","TBXU","BBH","LU1093756168.USD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167058424","title":"安进宣布Dazodalibep治疗中重度系统性干燥综合征的3期临床试验取得积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1167058424","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167058424?lang=zh_cn&edition=full","pubTime":"2026-09-22 21:04","pubTimestamp":1790082253,"startTime":"0","endTime":"0","summary":"安进公司今日发布重磅消息：其研发的Dazodalibep在针对中重度系统性干燥综合征的3期临床试验中，交出了一份令人振奋的答卷。这项研究聚焦于那些饱受病痛折磨的患者群体，而试验数据无疑为这片治疗荒漠带来了希望的甘霖。结果显示，与安慰剂组相比，接受Dazodalibep治疗的患者在关键疗效指标上均实现了统计学意义上的显著改善。分析人士指出，该药物的成功若能在后续环节得以延续，其市场潜力不容小觑，或将重新定义干燥综合征的治疗格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIB","IE0002141913.USD","IBB","IE00BJJMRZ35.SGD","BBH","LU1057294990.SGD","AMGN","LU1571399168.USD","PBE","IE00BJT1NW94.SGD","LU0109394709.USD","LU2089984988.USD","SG9999001440.SGD","IE00B2B36J28.USD","LU0122379950.USD","LU2242652126.USD","LU2468319806.SGD","TBXU","BK4566","PJP","BK4588","LU0058720904.USD","LU0868494617.USD","LU2242646821.SGD","LU0289739699.SGD","LU1023059063.AUD","LU1983299246.USD","IBBQ","IE0009355771.USD","LU0889565916.HKD","LU0320765992.SGD","LU2112291526.USD","BK4599","BK4581","IE00B4R5TH58.HKD","BK4585","BK4534","LU1061106388.HKD","BK4139","IE00BFTCPJ56.SGD","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196869155","title":"安进：Dazodalibep在系统性疾病活动方面展现出统计学显著且具有临床意义的改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1196869155","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196869155?lang=zh_cn&edition=full","pubTime":"2026-09-22 21:01","pubTimestamp":1790082073,"startTime":"0","endTime":"0","summary":"安进公司宣布，其实验性药物Dazodalibep在治疗中取得了重大突破。最新研究数据显示，该药物在改善系统性疾病活动方面，不仅达到了统计学上的显著效果，更在临床实践中展现出切实的改善意义。\n这一积极结果无疑为患者群体带来了新的希望，同时也为安进在竞争激烈的医药研发领域增添了重要砝码。相关研究的具体数据与详细分析，预计将在后续的医学会议或学术期刊中进一步披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242646821.SGD","IE0009355771.USD","IE00B2B36J28.USD","LU0058720904.USD","IE00BFTCPJ56.SGD","BBH","LU0109394709.USD","LU0868494617.USD","BK4566","LU1057294990.SGD","LU0122379950.USD","LU0889565916.HKD","BK4599","BK4534","LU2112291526.USD","BK4588","IE0002141913.USD","IE00BJJMRZ35.SGD","PJP","PBE","IBB","SG9999001440.SGD","BK4585","LU1983299246.USD","BK4139","BK4533","TBXU","IBBQ","LU0289739699.SGD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","AMGN","LU1571399168.USD","BK4581","LU2468319806.SGD","LU0320765992.SGD","LU1023059063.AUD","BIB","LU2089984988.USD","LU2242652126.USD","LU1061106388.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144298886","title":"安进：Dazodalibep治疗中重度症状性干燥综合征的Oasiz 303三期研究预计2026年第四季度完成","url":"https://stock-news.laohu8.com/highlight/detail?id=1144298886","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144298886?lang=zh_cn&edition=full","pubTime":"2026-09-22 21:00","pubTimestamp":1790082009,"startTime":"0","endTime":"0","summary":"安进（Amgen）披露，其针对中重度症状性干燥综合征（Sjögren's Disease）所开展的Dazodalibep三期临床研究——即Oasiz 303试验，预计将于2026年第四季度圆满完成。这一时间表的明确，为该公司在自身免疫疾病领域的管线推进提供了新的节点参照。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","PJP","BBH","BIB","BK4534","LU2468319806.SGD","BK4581","LU1571399168.USD","LU2089984988.USD","IE00BJJMRZ35.SGD","BK4599","BK4588","LU0320765992.SGD","BK4585","IE0002141913.USD","LU0109394709.USD","LU2242646821.SGD","LU0868494617.USD","IE0009355771.USD","LU1023059063.AUD","AMGN","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU1057294990.SGD","LU0058720904.USD","LU0122379950.USD","LU1061106388.HKD","LU1983299246.USD","BK4533","LU0289739699.SGD","IBBQ","PBE","BK4139","BK4566","LU2242652126.USD","LU2112291526.USD","SG9999001440.SGD","TBXU","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196050236","title":"福泰制药：Inaxaplin在两种AMKD患者队列中均展现良好安全性与耐受性","url":"https://stock-news.laohu8.com/highlight/detail?id=1196050236","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196050236?lang=zh_cn&edition=full","pubTime":"2026-09-22 20:02","pubTimestamp":1790078535,"startTime":"0","endTime":"0","summary":"福泰制药近日披露，其候选药物Inaxaplin在两项针对APOL1介导肾病的临床试验队列中，表现出令人满意的安全性和耐受性特征。业内观察人士指出，Inaxaplin若能在后续研究中持续印证其价值，有望为AMKD这一难治性疾病带来突破性治疗选择。福泰制药此番公告，不仅回应了市场对管线进展的关切，也再次凸显了其在精准医疗赛道上的深耕意图。随着更多数据的积累，Inaxaplin的临床定位将愈发清晰，其对患者生活质量的实际改善程度也将接受更严苛的检验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE00B2B36J28.USD","LU0058720904.USD","LU1069344957.HKD","IE00BFTCPJ56.SGD","BBH","LU0109394709.USD","LU0234570918.USD","SG9999001176.USD","LU2362540622.SGD","IE0002270589.USD","LU0061475181.USD","SGXZ57979304.SGD","LU0823416689.USD","LU0889565916.HKD","LU2237438978.USD","IE00BZ9MQY76.HKD","LU0417517546.SGD","LU2324357040.USD","LU2362541513.USD","SG9999013999.USD","LU2362541273.HKD","BK4588","TBXU","IE0002141913.USD","LU2456880835.USD","IE00BJJMRZ35.SGD","LU0079474960.USD","LU2417539215.USD","PBE","IBB","BK4585","VRTX","IE00B19Z3B42.SGD","BK4139","BK4533","IE00B19Z9Z06.USD","IBBQ","LU0289739699.SGD","LU1093756325.SGD","LU1674673691.USD","LU2236285917.USD","LU2462157665.USD","IE00B894F039.SGD","LU1035775433.USD","IDNA","BK4532","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","LU1585245621.USD","LU0256863811.USD","IE00B19Z9P08.USD","LU0432979614.USD","LU1778281490.HKD","LU1430594728.SGD","LU2468319806.SGD","BK4567","GNMX","LU0320765992.SGD","BIB","LU2089984988.USD","SG9999001176.SGD","IE00B19Z3581.USD","LU1674673428.USD","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160767959","title":"福泰制药公布Inaxaplin针对APOL1介导肾病（AMKD）其他人群的2B期AMPLIFIED研究积极结果，并完成2/3期AMPLITUDE试验入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1160767959","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160767959?lang=zh_cn&edition=full","pubTime":"2026-09-22 20:01","pubTimestamp":1790078494,"startTime":"0","endTime":"0","summary":"福泰制药今日宣布，其候选药物Inaxaplin在针对APOL1介导肾病其他患者群体的2B期AMPLIFIED研究中，取得了令人鼓舞的积极数据。与此同时，公司还确认，备受瞩目的2/3期AMPLITUDE注册试验已顺利达成全部患者入组目标。目前，该疾病在全球范围内缺乏针对性治疗手段，Inaxaplin有望为患者带来突破性的治疗选择。业内分析人士认为，AMPLIFIED研究的积极结果以及AMPLITUDE试验的顺利入组，进一步巩固了福泰制药在肾脏病精准医疗领域的领先地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNMX","BK4588","BIB","LU2468319806.SGD","LU1674673691.USD","LU0823416689.USD","LU2362541273.HKD","LU0061475181.USD","VRTX","LU1069344957.HKD","TBXU","LU0320765992.SGD","LU0234570918.USD","LU2089984988.USD","SG9999013999.USD","IE00B19Z9P08.USD","LU1093756168.USD","LU1430594728.SGD","BK4139","IE00BFTCPJ56.SGD","SGXZ57979304.SGD","BK4567","LU2456880835.USD","LU2236285917.USD","LU0058720904.USD","BK4585","BK4532","LU1585245621.USD","BBH","LU0079474960.USD","LU0889565916.HKD","IBBQ","IE00B4R5TH58.HKD","LU2324357040.USD","LU1674673428.USD","LU2362540622.SGD","IE00BJT1NW94.SGD","IE00B19Z9Z06.USD","LU0417517546.SGD","SG9999001176.USD","LU0256863811.USD","IE0002270589.USD","LU0432979614.USD","IE00BJJMRZ35.SGD","LU0109394709.USD","LU2462157665.USD","IE00B19Z3581.USD","PBE","IE00B2B36J28.USD","BK4533","IBB","IE0002141913.USD","IE00B894F039.SGD","LU0289739699.SGD","IE00B19Z3B42.SGD","LU1093756325.SGD","IE00BZ9MQY76.HKD","LU1778281490.HKD","LU2417539215.USD","LU2237438978.USD","SG9999001176.SGD","LU1035775433.USD","IE0009355771.USD","LU2362541513.USD","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191181268","title":"福泰制药：Inaxaplin显著降低UACR达42.7%——针对适度蛋白尿APKD患者展现积极疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1191181268","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191181268?lang=zh_cn&edition=full","pubTime":"2026-09-22 20:01","pubTimestamp":1790078474,"startTime":"0","endTime":"0","summary":"生物制药巨头福泰制药近日披露了一项令人瞩目的临床数据：其候选药物Inaxaplin在治疗伴有适度蛋白尿的常染色体显性多囊肾病患者中，于第13周时使尿白蛋白肌酐比较基线大幅下降42.7%。值得关注的是，这项数据凸显了Inaxaplin在降低蛋白尿方面的显著潜力，而蛋白尿正是衡量肾脏损伤程度及预测疾病进展风险的关键生物标志物。尽管现有数据展现出鼓舞人心的信号，但业界普遍认为，要全面评估Inaxaplin的长期获益与安全性，尚需更大规模、更长周期的临床验证。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","BK4588","LU0417517546.SGD","BK4139","IE00B2B36J28.USD","IE00B19Z3581.USD","IE00B4R5TH58.HKD","SG9999001176.SGD","LU2362541513.USD","LU1093756325.SGD","IE00B19Z9P08.USD","LU0109394709.USD","LU1674673428.USD","BIB","LU0823416689.USD","VRTX","GNMX","IE0002270589.USD","BK4585","LU2089984988.USD","IE00BJT1NW94.SGD","IE00B894F039.SGD","TBXU","LU1778281490.HKD","LU2417539215.USD","LU0320765992.SGD","BK4533","IE0009355771.USD","LU1430594728.SGD","LU1585245621.USD","IE00B19Z3B42.SGD","LU0889565916.HKD","LU0432979614.USD","LU2362541273.HKD","IBB","LU0079474960.USD","IE0002141913.USD","LU2456880835.USD","IE00BFTCPJ56.SGD","LU2468319806.SGD","BBH","SG9999001176.USD","LU0061475181.USD","IE00B19Z9Z06.USD","LU0289739699.SGD","LU2462157665.USD","LU2362540622.SGD","SG9999013999.USD","LU1035775433.USD","BK4567","LU0058720904.USD","LU0256863811.USD","BK4532","LU1069344957.HKD","LU1093756168.USD","LU1674673691.USD","LU2237438978.USD","LU2236285917.USD","IBBQ","PBE","IE00BJJMRZ35.SGD","LU0234570918.USD","IDNA","SGXZ57979304.SGD","IE00BZ9MQY76.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147475205","title":"福泰制药获Leerink Partners恢复覆盖，给予跑赢大盘评级及594美元目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1147475205","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147475205?lang=zh_cn&edition=full","pubTime":"2026-09-21 18:04","pubTimestamp":1789985058,"startTime":"0","endTime":"0","summary":"Leerink Partners近日宣布恢复对福泰制药的覆盖研究，并给予该股\"跑赢大盘\"评级。这家华尔街投行同时将目标价设定为594美元，彰显其对福泰制药未来走势的乐观预期。这一动作引发市场广泛关注——毕竟，Leerink Partners在生物医药领域的分析素以严谨著称。其恢复覆盖并给出积极评级，无疑为投资者注入了一针强心剂。值得注意的是，这一评级决定恰逢生物科技板块整体回暖之际。多重因素交织下，福泰制药的股价表现或将迎来新的催化剂。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE00B2B36J28.USD","LU0058720904.USD","LU1069344957.HKD","IE00BFTCPJ56.SGD","BBH","LU0109394709.USD","LU0234570918.USD","SG9999001176.USD","LU2362540622.SGD","IE0002270589.USD","LU0061475181.USD","SGXZ57979304.SGD","LU0823416689.USD","LU0889565916.HKD","LU2237438978.USD","IE00BZ9MQY76.HKD","LU0417517546.SGD","LU2324357040.USD","LU2362541513.USD","SG9999013999.USD","LU2362541273.HKD","BK4588","TBXU","IE0002141913.USD","LU2456880835.USD","IE00BJJMRZ35.SGD","LU0079474960.USD","LU2417539215.USD","PBE","IBB","BK4585","VRTX","IE00B19Z3B42.SGD","BK4139","BK4533","IE00B19Z9Z06.USD","IBBQ","LU0289739699.SGD","LU1093756325.SGD","LU1674673691.USD","LU2236285917.USD","LU2462157665.USD","IE00B894F039.SGD","LU1035775433.USD","IDNA","BK4532","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","LU1585245621.USD","LU0256863811.USD","IE00B19Z9P08.USD","LU0432979614.USD","LU1778281490.HKD","LU1430594728.SGD","LU2468319806.SGD","BK4567","GNMX","LU0320765992.SGD","BIB","LU2089984988.USD","SG9999001176.SGD","IE00B19Z3581.USD","LU1674673428.USD","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164691459","title":"吉利德科学扩大六项免许可费自愿授权协议，力推每年一次HIV预防药Lenacapavir","url":"https://stock-news.laohu8.com/highlight/detail?id=1164691459","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164691459?lang=zh_cn&edition=full","pubTime":"2026-09-16 20:31","pubTimestamp":1789561872,"startTime":"0","endTime":"0","summary":"吉利德科学宣布，扩大其六项免许可费的自愿授权协议，覆盖其每年仅需注射一次的HIV预防药物Lenacapavir。此举旨在拓宽药物可及性，助力全球抗击艾滋病疫情。通过这一系列协议，吉利德希望加快该长效预防方案在中低收入国家的推广，以应对持续存在的公共卫生挑战。该举措不仅彰显了公司在全球健康公平方面的承诺，也为实现2030年终结艾滋病流行的目标注入新动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1037948541.HKD","LU2357627491.SGD","LU0965509101.SGD","SG9999015945.SGD","LU2087621335.USD","TBXU","LU1585245621.USD","LU0965508806.USD","GILD","IE00B19Z3B42.SGD","LU0965509010.AUD","LU2468319806.SGD","SG9999015986.USD","BK4550","BK4583","LU1057294990.SGD","LU2089984988.USD","LU1430594728.SGD","LU1061106388.HKD","SG9999015952.SGD","IE00BSNM7G36.USD","LU1934455277.USD","TMED","LU1066053197.SGD","LU1571399168.USD","BMED","IE0002270589.USD","BK4568","BK4585","IE00B7SZLL34.SGD","LU0114720955.EUR","LU0859254822.USD","BK4139","LU0882574055.USD","IBBQ","LU1934455194.USD","BIB","LU0320765992.SGD","LU0823416689.USD","BK4532","BK4578","LU2112291526.USD","LU0289739699.SGD","LU1934455863.HKD","SG9999015978.USD","LU0889565916.HKD","LU0234570918.USD","LU1674673428.USD","LU0122379950.USD","LU1778281490.HKD","LU0861579265.USD","IE00B3T34201.USD","LU1023059063.AUD","IBB","LU0058720904.USD","BK4588","IE00BZ1G4Q59.USD","LU1066051498.USD","LU2324357040.USD","LU1037948897.HKD","MEDI","BBH","BK4566","LU1674673691.USD","IE00BKVL7J92.USD","LU0965509283.SGD","IE00B19Z3581.USD","LU1839511570.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667267605","title":"百时美施贵宝就安进拟推出的Opdivo生物类似药提起诉讼","url":"https://stock-news.laohu8.com/highlight/detail?id=2667267605","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667267605?lang=zh_cn&edition=full","pubTime":"2026-09-16 10:15","pubTimestamp":1789524901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00BSNM7G36.USD","BK4566","LU1670711123.USD","LU1989771016.USD","IE0009355771.USD","LU2272731600.USD","LU1868837300.USD","LU1236620750.USD","LU2468319806.SGD","IBBQ","BK4585","BK4588","BK4559","FTXH","LU1868836757.USD","BK4533","LU2272731865.HKD","LU0225771236.USD","BK4139","BK4534","LU1261432733.SGD","TBXU","BIB","LU1992135399.USD","LU0320765992.SGD","LU2322448957.HKD","LU0061475181.USD","LU1868836591.USD","LU0058720904.USD","LU2473716301.USD","BBH","IBB","LU1023059063.AUD","LU1236620834.HKD","IHE","IE00B4R5TH58.HKD","XPH","LU2125154778.USD","LU0109394709.USD","LU0289739699.SGD","LU0868494617.USD","LU1983299246.USD","PPH","PJP","LU0225284248.USD","BMY","AMGN","PBE","LU1883839398.USD","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120765496","title":"吉利德科学携手巴西卫生部，共促Lenacapavir本地化生产新篇章","url":"https://stock-news.laohu8.com/highlight/detail?id=1120765496","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120765496?lang=zh_cn&edition=full","pubTime":"2026-09-15 23:15","pubTimestamp":1789485331,"startTime":"0","endTime":"0","summary":"吉利德科学公司近日透露，正积极与巴西卫生部探索合作良机，旨在助力该国实现Lenacapavir药物的本土生产愿景。这一举措，无疑为巴西医药产业自主化进程注入了强劲动力。据悉，双方的洽谈聚焦于如何深化协作，以切实推进巴西卫生部既定的战略目标——即构建并强化Lenacapavir的本地制造能力。Lenacapavir，作为一款备受瞩目的长效抗逆转录病毒药物，其本地化生产若能落地，对巴西乃至更广泛地区的HIV防治工作意义深远。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4566","IE00B19Z3B42.SGD","SG9999015945.SGD","LU1934455863.HKD","SG9999015952.SGD","LU1934455194.USD","MEDI","SG9999015978.USD","LU2087621335.USD","LU2468319806.SGD","TMED","LU2112291526.USD","BIB","BBH","BK4550","IE00BZ1G4Q59.USD","LU1023059063.AUD","GILD","BK4585","LU1839511570.USD","LU0882574055.USD","BK4139","LU0965509101.SGD","LU1585245621.USD","LU2357627491.SGD","LU0965509283.SGD","LU0889565916.HKD","IE00B3T34201.USD","LU1430594728.SGD","LU1571399168.USD","BK4583","LU1057294990.SGD","IE00B7SZLL34.SGD","LU0965509010.AUD","LU1674673691.USD","LU0823416689.USD","TBXU","BK4568","IBB","IE00B19Z3581.USD","LU1037948541.HKD","LU0114720955.EUR","IBBQ","IE00BSNM7G36.USD","LU1061106388.HKD","LU1778281490.HKD","LU0122379950.USD","LU0320765992.SGD","LU1037948897.HKD","BK4578","BK4588","BMED","LU0861579265.USD","LU0289739699.SGD","LU1674673428.USD","LU1934455277.USD","LU2089984988.USD","IE0002270589.USD","SG9999015986.USD","LU1066051498.USD","LU0234570918.USD","LU0965508806.USD","LU2324357040.USD","IE00BKVL7J92.USD","LU0859254822.USD","LU1066053197.SGD","LU0058720904.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158863992","title":"吉利德科学：持续探索与泛美卫生组织合作，助力各国准备好并扩大长效艾滋病预防措施的普及","url":"https://stock-news.laohu8.com/highlight/detail?id=1158863992","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158863992?lang=zh_cn&edition=full","pubTime":"2026-09-15 23:15","pubTimestamp":1789485330,"startTime":"0","endTime":"0","summary":"吉利德科学（Gilead Sciences）宣布，将继续探索与泛美卫生组织（PAHO）的合作机会，以支持各国做好充分准备，并推动长效艾滋病预防手段的可及性扩展。这一举措旨在强化全球公共卫生应对体系，尤其是针对中低收入国家的需求，通过技术转移、能力建设及供应链优化等途径，加快长效预防方案的落地与规模化应用。双方的合作重点在于应对实施层面的挑战，确保相关资源能够高效、公平地分配至最需要的人群，从而在更大范围内遏制HIV的传播。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1934455863.HKD","LU2089984988.USD","LU0859254822.USD","LU0114720955.EUR","LU1839511570.USD","SG9999015952.SGD","LU0882574055.USD","LU0122379950.USD","BK4139","LU1037948541.HKD","IE00B19Z3581.USD","LU0320765992.SGD","LU1674673428.USD","BIB","IE00B7SZLL34.SGD","LU0861579265.USD","LU1585245621.USD","LU2468319806.SGD","IBB","LU2324357040.USD","BK4588","LU0058720904.USD","LU0289739699.SGD","LU1023059063.AUD","LU1674673691.USD","LU1061106388.HKD","LU1571399168.USD","LU1066053197.SGD","GILD","BK4566","IE0002270589.USD","LU1057294990.SGD","LU2357627491.SGD","BBH","BK4550","BK4578","LU1430594728.SGD","LU0823416689.USD","LU2112291526.USD","BK4585","LU1934455194.USD","LU1037948897.HKD","BK4583","MEDI","LU1778281490.HKD","SG9999015945.SGD","SG9999015986.USD","LU0109394709.USD","LU0889565916.HKD","IE00BSNM7G36.USD","SG9999015978.USD","LU0965509010.AUD","TBXU","IE00B3T34201.USD","LU0965509101.SGD","LU1934455277.USD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU0965508806.USD","BK4568","LU1066051498.USD","IBBQ","TMED","LU2087621335.USD","BK4532","LU0234570918.USD","BMED","IE00B19Z3B42.SGD","LU0965509283.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667623020","title":"吉利德科学公司高管在电话会议上表示，HIV药物市场的增长预计将在未来几个季度内回归至2%至3%的正常水平。","url":"https://stock-news.laohu8.com/highlight/detail?id=2667623020","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667623020?lang=zh_cn&edition=full","pubTime":"2026-09-15 23:11","pubTimestamp":1789485099,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0889565916.HKD","LU0965509283.SGD","SG9999015978.USD","BK4568","IE00B7SZLL34.SGD","LU1839511570.USD","LU1934455863.HKD","BK4532","LU1066051498.USD","IE00BKVL7J92.USD","BMED","LU1037948897.HKD","BIB","IE00B19Z3581.USD","LU0965509101.SGD","BK4588","LU1674673691.USD","LU0859254822.USD","IBB","LU1037948541.HKD","LU2112291526.USD","LU1057294990.SGD","LU1934455277.USD","LU1585245621.USD","LU0289739699.SGD","LU1674673428.USD","IE00B19Z3B42.SGD","LU1061106388.HKD","LU0882574055.USD","TMED","IE0002270589.USD","BK4566","LU0965509010.AUD","LU1066053197.SGD","IBBQ","GILD","LU0058720904.USD","LU0320765992.SGD","BK4550","SG9999015952.SGD","LU0122379950.USD","LU2324357040.USD","TBXU","BK4139","LU0114720955.EUR","LU1430594728.SGD","SG9999015945.SGD","LU0234570918.USD","BBH","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159280995","title":"吉利德科学携手泛美卫生组织，加速拉美及加勒比地区HIV预防药物Lenacapavir的可及性","url":"https://stock-news.laohu8.com/highlight/detail?id=1159280995","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159280995?lang=zh_cn&edition=full","pubTime":"2026-09-15 23:10","pubTimestamp":1789485009,"startTime":"0","endTime":"0","summary":"吉利德科学（Gilead Sciences）日前宣布，与泛美卫生组织（PAHO）达成一项战略合作。此番联手，旨在显著提升一年两针的HIV预防药物Lenacapavir在拉丁美洲及加勒比地区的可及性。双方的合作，将为该区域的高风险人群带来更便捷的预防选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234570918.USD","LU2089984988.USD","BK4139","IBBQ","LU0965509283.SGD","IBB","LU1430594728.SGD","LU1934455194.USD","BIB","LU1061106388.HKD","LU1066051498.USD","IE0002270589.USD","LU1585245621.USD","LU0965509101.SGD","BBH","LU0889565916.HKD","IE00B19Z3B42.SGD","LU1674673691.USD","LU1839511570.USD","LU0320765992.SGD","SG9999015945.SGD","BK4583","LU2468319806.SGD","IE00BKVL7J92.USD","IE00B3T34201.USD","IE00BSNM7G36.USD","IE00BZ1G4Q59.USD","LU0289739699.SGD","LU0965508806.USD","LU1778281490.HKD","LU1934455277.USD","SG9999015952.SGD","LU1066053197.SGD","SG9999015986.USD","LU1023059063.AUD","LU2112291526.USD","LU0058720904.USD","BK4585","LU2324357040.USD","LU0122379950.USD","IE00B19Z3581.USD","BK4568","LU0114720955.EUR","LU0965509010.AUD","BMED","GILD","BK4532","LU2357627491.SGD","SG9999015978.USD","BK4578","TBXU","LU1037948541.HKD","LU1674673428.USD","BK4588","LU0882574055.USD","LU0861579265.USD","LU0823416689.USD","LU1057294990.SGD","LU1934455863.HKD","LU0109394709.USD","TMED","LU0859254822.USD","LU1571399168.USD","MEDI","IE00B7SZLL34.SGD","BK4550","LU1037948897.HKD","LU2087621335.USD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153389014","title":"吉利德高管表示，未来几个季度HIV市场增长或将回归2%-3%常态水平","url":"https://stock-news.laohu8.com/highlight/detail?id=1153389014","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153389014?lang=zh_cn&edition=full","pubTime":"2026-09-15 23:09","pubTimestamp":1789484948,"startTime":"0","endTime":"0","summary":"吉利德高管在电话会议中透露，该公司预计HIV治疗市场的增长势头将在未来几个季度内逐步趋于稳定，最终回到2%至3%的年增长区间。这一表态正值市场对HIV药物需求持续波动的关键节点。高管指出，当前的增长水平仍高于长期趋势，但随着时间推移，这种偏热的状态将逐渐降温。整个行业的扩张速度，预计将在近期内回落至更为可持续的轨道上。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0234570918.USD","LU1778281490.HKD","BK4532","BK4568","LU0109394709.USD","LU1057294990.SGD","LU1839511570.USD","LU1934455277.USD","LU0889565916.HKD","LU0965508806.USD","LU2087621335.USD","LU1585245621.USD","BMED","LU0965509010.AUD","LU1571399168.USD","LU0965509283.SGD","BK4583","LU2468319806.SGD","LU1674673428.USD","LU0058720904.USD","LU2089984988.USD","SG9999015945.SGD","LU0861579265.USD","TMED","LU1066053197.SGD","LU1066051498.USD","IE00BSNM7G36.USD","IE00B19Z3581.USD","BK4139","BK4588","BBH","SG9999015986.USD","IBB","BIB","IE00BKVL7J92.USD","LU2112291526.USD","IE0002270589.USD","IBBQ","LU1037948541.HKD","LU0289739699.SGD","IE00BZ1G4Q59.USD","LU1037948897.HKD","IE00B7SZLL34.SGD","LU1934455863.HKD","LU0823416689.USD","TBXU","LU0882574055.USD","LU2324357040.USD","LU1674673691.USD","LU1934455194.USD","MEDI","BK4585","LU1430594728.SGD","LU2357627491.SGD","LU0859254822.USD","LU0965509101.SGD","BK4578","SG9999015952.SGD","SG9999015978.USD","IE00B3T34201.USD","BK4550","GILD","LU1023059063.AUD","BK4566","IE00B19Z3B42.SGD","LU0114720955.EUR","LU1061106388.HKD","LU0122379950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131138631","title":"吉利德高管透露：周服HIV预防药物有望2027年第一季度上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1131138631","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131138631?lang=zh_cn&edition=full","pubTime":"2026-09-15 23:05","pubTimestamp":1789484737,"startTime":"0","endTime":"0","summary":"吉利德科学高管在电话会议中表示，其每周口服HIV预防药物预计将于2027年第一季度正式推出。这一表态为公司抗艾药物管线注入了新的期待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","GILD","IE00BKVL7J92.USD","LU1057294990.SGD","SG9999015986.USD","LU0823416689.USD","LU0889565916.HKD","TBXU","LU1674673691.USD","BMED","BK4588","LU0965509283.SGD","LU1934455194.USD","BK4568","LU1778281490.HKD","LU0114720955.EUR","BK4532","LU0882574055.USD","IE00B19Z3B42.SGD","LU0861579265.USD","SG9999015952.SGD","LU1430594728.SGD","LU2324357040.USD","LU1037948541.HKD","LU0965509010.AUD","LU1066051498.USD","BK4139","IE00B19Z3581.USD","BK4583","LU0965508806.USD","LU2112291526.USD","IE00BZ1G4Q59.USD","BK4566","LU0859254822.USD","IE0002270589.USD","LU0122379950.USD","LU0234570918.USD","LU2357627491.SGD","LU1061106388.HKD","IBB","LU1023059063.AUD","LU1585245621.USD","LU2089984988.USD","BIB","LU0058720904.USD","MEDI","IE00B7SZLL34.SGD","LU0320765992.SGD","IBBQ","TMED","BK4578","LU1839511570.USD","LU1934455277.USD","IE00BSNM7G36.USD","LU0965509101.SGD","LU2468319806.SGD","LU1571399168.USD","IE00B3T34201.USD","LU1934455863.HKD","LU1066053197.SGD","BK4550","BK4585","LU0109394709.USD","LU0289739699.SGD","LU2087621335.USD","LU1037948897.HKD","SG9999015945.SGD","SG9999015978.USD","LU1674673428.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666571008","title":"阿斯利康股价盘后跌超2%，因其三期临床试验结果令人失望。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666571008?lang=zh_cn&edition=full","pubTime":"2026-09-12 04:23","pubTimestamp":1789158183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBB","LU2322448791.USD","TMED","PBE","SBIO","PJP","IDNA","PBPH","LFSC","BIOY","LU2272731782.SGD","IE00B5TLWC47.USD","LU2272731600.USD","MEDI","FBT","WDNA","CANC","BBH","MRNY","RSPH","BIB","IEIH","IEHS","GNOM","MRNX","LU1992135399.USD","LU1992135472.HKD","HELX","LU2272731865.HKD","PPH","XBIX","AZNH","IBRN","BBP","LU2322448957.HKD","BK4588","PSCH","SYNB","XPH","RXL","BME","LU2473716301.USD","IYH","BK4585","FTXH"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.proshares.com/funds/bib.html","stockEarnings":[{"period":"1week","weight":0.0305},{"period":"1month","weight":-0.0098},{"period":"3month","weight":0.0806},{"period":"6month","weight":0.4119},{"period":"1year","weight":0.9382},{"period":"ytd","weight":0.4471}],"compareEarnings":[{"period":"1week","weight":-0.0067},{"period":"1month","weight":-0.0058},{"period":"3month","weight":0.024},{"period":"6month","weight":0.1628},{"period":"1year","weight":0.1448},{"period":"ytd","weight":0.1184}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.04688},{"month":2,"riseRate":0.5,"avgChangeRate":0.00449},{"month":3,"riseRate":0.4375,"avgChangeRate":-0.010634},{"month":4,"riseRate":0.5625,"avgChangeRate":0.01003},{"month":5,"riseRate":0.529412,"avgChangeRate":0.011921},{"month":6,"riseRate":0.705882,"avgChangeRate":0.044992},{"month":7,"riseRate":0.647059,"avgChangeRate":0.05944},{"month":8,"riseRate":0.529412,"avgChangeRate":0.010833},{"month":9,"riseRate":0.352941,"avgChangeRate":-0.006931},{"month":10,"riseRate":0.4375,"avgChangeRate":-0.005173},{"month":11,"riseRate":0.8125,"avgChangeRate":0.085975},{"month":12,"riseRate":0.5,"avgChangeRate":-0.001322}],"exchange":"NASDAQ","name":"Ultra纳斯达克生物科","nameEN":"ProShares Ultra Nasdaq Biotechnology"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ultra纳斯达克生物科(BIB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Ultra纳斯达克生物科(BIB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Ultra纳斯达克生物科,BIB,Ultra纳斯达克生物科股票,Ultra纳斯达克生物科股票老虎,Ultra纳斯达克生物科股票老虎国际,Ultra纳斯达克生物科行情,Ultra纳斯达克生物科股票行情,Ultra纳斯达克生物科股价,Ultra纳斯达克生物科股市,Ultra纳斯达克生物科股票价格,Ultra纳斯达克生物科股票交易,Ultra纳斯达克生物科股票购买,Ultra纳斯达克生物科股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ultra纳斯达克生物科(BIB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Ultra纳斯达克生物科(BIB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}